Lurbinectedin is a medication used to treat certain types of cancer. According to the sources provided, it is administered intravenously, which means it is injected into a vein through a needle. The recommended dosage and administration schedule may vary depending on the patient's medical condition and other factors. It is important to follow the instructions provided by the healthcare provider who is administering the medication.

The drug is protected by a patent, which means that only the patent holder has the right to manufacture and sell it. Lurbinectedin is marketed under the brand name Zepzelca. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in adult patients who have previously received chemotherapy.

In summary, lurbinectedin is administered intravenously and is only available under the brand name Zepzelca. It is used to treat metastatic small cell lung cancer in adult patients who have previously received chemotherapy. It is important to follow the healthcare provider's instructions when taking this medication.

Sources:
[1] Drug Patent Watch. (n.d.). LURBINECTEDIN. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] MedlinePlus. (2021, March 15). Lurbinectedin Injection: MedlinePlus Drug Information. Retrieved from https://medlineplus.gov/druginfo/meds/a620049.html
[3] U.S. Food and Drug Administration. (2020). ZEPZELCA (lurbinectedin) injection, for intravenous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf